OncoHost is advancing a new paradigm in precision oncology.
The PROphet® platform combines AI and plasma proteomic profiling to assign a PROphet® Score, a
measure of the predicted clinical benefit from anti-PD-1/PD-L1 treatment correlated to the patient’s
overall survival, and list clinical evidence-based treatment considerations.
The PROphet® platform combines AI and plasma proteomic profiling to assign a PROphet® Score, a
measure of the predicted clinical benefit from anti-PD-1/PD-L1 treatment correlated to the patient’s
overall survival, and list clinical evidence-based treatment considerations.

Plasma Proteomic Profiling
Analyzing the biological interplay of the patient, tumor, and therapy can:

Enable early prediction
of individual response to
anti-PD-1/PD-L1 immunotherapy
of individual response to
anti-PD-1/PD-L1 immunotherapy

Provide actionable
clinical insights and
optimal therapy choices
clinical insights and
optimal therapy choices

A new approach to
managing therapeutic strategies

Blood-based test

Not exclusive to
mutation carriers
mutation carriers

Personalized
PROphet® Report
PROphet® Report

Predictive
clinical insights
clinical insights

Clinical evidence-
based treatment
considerations
based treatment
considerations